Arch Nears First Clinical Trial of AB569 as Treatment for Antibiotic-Resistant Lung Bacteria
Read about Arch Biopartners preparing for its first clinical trial of AB569 to treat antibiotic-resistant bacteria in the lungs of cystic fibrosis patients.
0 Comments